Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 80

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 8
Chunk 80
---
)(366)Amortization of intangible assets(441)(299)(96)— (836)Impairments(b)(15)(432)— — (447)Other segment expenses(c)(1,962)(2,674)(3,190)(168)(7,994)Operating profit (loss)$972 $(38)$1,272 $(172)$2,034 For the Six-Month Period Ended June 28, 2024:Sales$3,237 $3,515 $4,787 $— $11,539 Less:Depreciation(77)(79)(197)(4)(357)Amortization of intangible assets(432)(281)(96)— (809)Other segment expenses(c)(1,941)(2,687)(3,108)(157)(7,893)Operating profit (loss)$787 $468 $1,386 $(161)$2,480 (a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance.(b) For information on the impairments, refer to Note 8. (c) Other segment expenses for each reportable segment include cost of sales, selling, general and administrative (“SG&A”) expenses and research and development (“R&D”) expenses, excluding in each case depreciation, amortization of intangible assets and impairments.  Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses. The following table presents identifiable assets as of June 27, 2025 and December 31, 2024 ($ in millions):June 27, 2025December 31, 2024Identifiable assets:Biotechnology$37,562 $34,605 Life Sciences23,397 23,211 Diagnostics14,537 14,204 Other6,124 5,522 Total$81,620 $77,542 The following table presents capital expenditures for the three and six-month periods ended June 27, 2025 and June 28, 2024 ($ in millions):Three-Month Period EndedSix-Month Period EndedJune 27, 2025June 28, 2024June 27, 2025June 28, 2024Capital expenditures:Biotechnology$80 $111 $161 $213 Life Sciences41 50 89 110 Diagnostics125